Just to clarify... there were several webinars last week with AABB, ASFA and US FDA.
The collection of CCP (COVID Convalescent Plasma) is no different from the collection of ANY plasma. So blood centers can collect it as they would like. It doesn't require anything special if you've been collecting plasma.
Most centers are collecting as much as they can once they get a donor (up to 1L) as a standard "dose" seems to be somewhere in the 300-400 mL range.
It is the TRANSFUSION of the product that requires the IND, and the FDA has promised that they will be approved in 4-8 hours. They need to be submitted and approved on a per-patient basis.
Many blood centers are working now to locate recovered patients and collect plasma. It can then be frozen and a standing inventory in place.
In Australia, if you want to start doing something now... I would start getting an inventory of CCP.
In the US, because of HIPPA (patient privacy) blood centers are having to contact doctors to contact their patients to see if they would be willing to donate and those donors then need to call the blood center. They are testing these "donors" for antibody titers and if it's been <28 days since the onset of symptoms, they are also testing to make sure the virus itself isn't present (so a negative RNA test). Locating these donors and doing the required testing is taking some time. Once found, it's pretty quick and easy process to get the plasma. Then it's a normal process to get it to the hospitals.
It's looking like it's best to transfuse them earlier than later. There is no standard of care... but I would suspect that the best results will be seen if they can be transfused as soon as they're admitted to the hospital (those not admitted may not be sick enough to need this?).
As for billing... your guess is as good as mine.